Summary of
Exogenous D-β-hydroxybutyrate Lowers Blood Glucose by Reducing L-Alanine Availability for Gluconeogenesis
By
Purpose
To determine whether exogenous D-β-hydroxybutyrate (BHB) lowers blood glucose by reducing plasma L-alanine, a key gluconeogenic substrate.
Methods
In a randomized crossover trial, healthy adult participants consumed a ketone monoester drink (ΔG®) either alone or with added L-alanine. Plasma levels of BHB, glucose, and amino acids were measured over time to assess metabolic effects.
Results
BHB ingestion significantly increased plasma BHB levels and reduced both blood glucose and plasma L-alanine concentrations. When L-alanine was co-administered with BHB, the glucose-lowering effect was attenuated, suggesting that BHB limits gluconeogenesis in part by depleting substrate availability.
Conclusion
Exogenous BHB lowers blood glucose by reducing plasma L-alanine, thereby limiting hepatic gluconeogenesis. This mechanism may underlie ketones’ therapeutic potential in managing blood sugar without triggering hypoglycemia or requiring insulin.